4/A: Fennec Pharmaceuticals COO Corrects Transaction Code in Form 4 Amendment

Adrian Haigh, COO of Fennec Pharmaceuticals, files an amended Form 4 to correct the transaction code for common share acquisitions on April 17 and 18, 2024.

Summary

• Adrian Haigh, the Chief Operating Officer of Fennec Pharmaceuticals, filed an amendment to a previously submitted Form 4.
• The amendment corrects the transaction code for the acquisition of common shares on April 17 and April 18, 2024.
• The original filing incorrectly indicated the transaction code as 'S', but the corrected code is 'M'.
• The acquisitions were made through option exercises pursuant to a 10b5-1 plan dated August 17, 2023.
• Haigh acquired 22,222 common shares on April 17, 2024, and another 22,222 common shares on April 18, 2024, at a price of $2.31 per share.

Sentiment

Score: 7

Explanation: The document is a routine correction of a regulatory filing, indicating standard corporate governance practices. The sentiment is neutral to slightly positive as it reflects attention to detail and compliance.

Industry Context

Form 4 filings are standard practice for company insiders to report transactions in their company's stock, ensuring transparency and compliance with SEC regulations.

Stakeholder Impact

• The correction of the transaction code ensures accurate reporting to shareholders and the public.

Key Dates